In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

Nowak-Göttl, Ulrike

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. [electronic resource] - Blood Dec 2010 - 6101-5 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1528-0020

10.1182/blood-2010-05-283861 doi


Adolescent
Adult
Age Factors
Anticoagulants--administration & dosage
Aryl Hydrocarbon Hydroxylases--genetics
Child
Child, Preschool
Cohort Studies
Cytochrome P-450 CYP2C9
Genotype
Humans
Infant
Infant, Newborn
Mixed Function Oxygenases--genetics
Phenprocoumon--administration & dosage
Polymorphism, Genetic--genetics
Prognosis
Prospective Studies
Thrombosis--drug therapy
Vitamin K--antagonists & inhibitors
Vitamin K Epoxide Reductases
Warfarin--administration & dosage
Young Adult